Summary of Cost ($) and Outcome Results in the base-case analysis
| Strategy | Cost | Expected LYs | QALYs | ICERa | Comments |
|---|---|---|---|---|---|
| United States | |||||
| Sunitinib | 297,693 | 3.01 | 2.04 | NA | Cost-effective |
| Nivolumab plus ipilimumab | 362,807 | 4.18 | 2.80 | 85,506 | |
| United Kingdom | |||||
| Sunitinib | 75,034 | 3.01 | 2.02 | NA | Not cost-effective |
| Nivolumab plus ipilimumab | 169,390 | 4.18 | 2.77 | 126,499 | |
| China | |||||
| Sunitinib | 97,846 | 3.01 | 1.96 | NA | Cost-effective |
| Nivolumab plus ipilimumab | 101,132 | 4.18 | 2.66 | 4682 | |
aIncremental cost per QALY. LY, life years; QALY, quality-adjusted life-years